DANIELLE JENKINS: Open Payments
NPI 1104401025 · GREENBRIER, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$612 in 22 payments from 10 companies in 2025. Trend: 2023 $707 · 2024 $434 · 2025 $612
Food & beverage: $612
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $156 |
| Axsome Therapeutics, Inc. | 4 | $156 |
| Janssen Pharmaceuticals, Inc | 3 | $76 |
| ABBVIE INC. | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: CAPLYTA, Auvelity, SPRAVATO, REXULTI, VRAYLAR, HETLIOZ, Qelbree, Quviviq.
Industry payments across AR — which companies pay providers there.
